Cardiometabolic disorders and weight: A complex constellation of interrelated conditions

Article

This constellation of conditions-cardiometabolic disorders and weight-has become one of the most pressing public health issues today, affecting approximately a quarter of the U.S. population, accounting for a substantial proportion of health-care and prescription drug spending, and threatening the vitality of an aging population.

Key Points

An estimated 47 million Americans have double the average risk of heart disease because they are affected by a complex constellation of interrelated conditions, including obesity, impaired glucose metabolism, hypertension, and lipid disorders.1 These patients also are five times more likely to develop diabetes, according to the National Heart, Lung, and Blood Institute.1

This constellation of conditions-cardiometabolic disorders and weight (CMDW)-has become one of the most pressing public health issues today, affecting approximately a quarter of the U.S. population, accounting for a substantial proportion of health-care and prescription drug spending, and threatening the vitality of an aging population.1,2

Obesity

Recent research indicates that excess visceral adipose tissue releases metabolites, cytokines, chemokines, and hormones that influence inflammation and other factors to affect atherogenesis and the vessel wall directly.6

In an effort to slow the obesity epidemic, 19 states have set stricter nutritional standards for school meals, 27 states have nutritional standards for foods sold in schools, and 20 now require body mass index screening or other weight assessment of schoolchildren.7

Impaired glucose metabolism

In the United States, 17.9 million patients have diagnosed diabetes; an estimated 5.7 million cases remain undiagnosed, and an additional 57 million people have prediabetes, according to the American Diabetes Association.8 The incidence of diabetes among those aged 60 years or more is 23.1%. An estimated 16.5% of the adult American Indian and Alaska native population are affected by diabetes.8 After adjusting for age differences, the prevalence of diabetes is 11.8% among non-Hispanic blacks, 10.4% among Hispanic Americans, 7.5% in Asian Americans, and 6.6% among non-Hispanic whites.8

Overall, approximately 210,000 Americans aged more than 20 years have diabetes, an incidence of 0.26%, but the data do not differentiate between diabetes types.8 Type 2 diabetes, however, is being diagnosed more frequently in children, especially among Native Americans and African and Hispanic Americans. In addition, one in six overweight adolescents-approximately 2 million-have prediabetes.8

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, July 10-12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
© 2025 MJH Life Sciences

All rights reserved.